This study highlights the importance of looking at the balance between complement activation (e.g., MAC complex) and regulation (e.g. CD 59) in evaluating complement biomarkers and suggests C3, CFI and C9-to-CD59 ratio may be a marker of tubulointerstitial disease in lupus nephritis. The gene discussed is CD59; the disease is lupus nephritis.